MARKETS / NYSE / A

NYSE · LABORATORY ANALYTICAL INSTRUMENTS · LARGE CAP

Agilent Technologies, Inc. A

19 fiscal years on record · USD · FY2025 reported · SEC filings only

10 YEARS OF DIVIDEND GROWTH

Revenue

$6.9B

▲ 6.7% YoY

Net income

$1.3B

▲ 1.1% YoY

Free cash flow

$1.2B

▼ 16.1% YoY

In brief

What this company does

Agilent Technologies, Inc. provides application-focused solutions, including instruments, software, services and consumables, for the entire laboratory workflow. As of October 31, 2025, it employed approximately 18,100 people, of whom approximately 7,100 were based in the Americas, 4,400 in Europe and 6,600 in Asia Pacific. Following a November 2024 reorganization, the company has three business segments, each a reportable segment: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Agilent Technologies, Inc. was incorporated in Delaware in May 1999.

Written from the business description in AGILENT TECHNOLOGIES, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 22 December 2025. Every sentence was checked against that document before publication.

Growth

USD 6.9B

Revenue, FY2025 · full 19-year series below

Revenue $B Net income $B

FY2025 · Revenue 6.9 · Net income 1.3

Compound annual growth

Revenue

+0.5%

+5.4%

+5.6%

+1.6%

Net income

+1.3%

+12.6%

EPS, diluted

+3.0%

+14.7%

+14.3%

+5.9%

Dividend / share

+5.7%

+6.6%

+9.5%

Returned to shareholders

−20.2%

+0.5%

+5.9%

+3.7%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +5.4% a year over five years — but profit grew faster: net income at +12.6%, earnings per share at +14.7%.

The share count fell from 0.31B to 0.28B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

19 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 21.3% · Net 18.8%

ROE

FY2025 · ROE 20.6%

Gross margin52.4%

Operating margin21.3%

Net margin18.8%

Return on assets10.6%

EBITDAUSD 1.8B

Each USD of equity produced 21 cents of profit this year.

Cash & shareholders

USD 707.0M

returned in FY2025 · dividends + net buybacks

Free cash flow $B

FY2025 · FCF 1.2

Net buybacks $B Dividends $B

FY2025 · Dividends 0.3 · Net buybacks 0.4

Dividends paidUSD 282.0M

Net buybacksUSD 425.0M

Share of profit54.3%

Consecutive raises10 years

USD 282.0M in dividends and USD 425.0M in buybacks — 54% of the year's profit went back to shareholders.

Total assetsUSD 12.7B

EquityUSD 6.7B

CashUSD 1.8B

Gross debtUSD 3.4B

Net debtUSD 1.6B

Current ratio1.96×

Net debt stands at 23% of equity.

The 19-year record

19 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue $B	6.9	6.5	6.8	6.8	6.3	5.3	5.2	4.9	4.5	4.2	4.0	4.0	3.9	6.9	6.6	5.4	4.5	5.8	5.4
Operating income $B	1.5	1.5	1.4	1.6	1.3	0.8	0.9	0.9	0.8	0.6	0.5	0.4	0.4	1.1	1.1	0.6	0.0	0.8	0.6
EBITDA $B	1.8	1.7	1.6	1.9	1.7	1.2	1.2	1.1	1.0	0.9	0.8	0.8	0.8	1.4	1.3	0.8	0.2	1.0	0.8
Income tax $B	0.1	0.2	0.1	0.2	0.1	0.1	−0.2	0.6	0.1	0.1	0.0	−0.0	0.1	−0.1	0.0	0.0	0.0	0.1	0.0
Net income $B	1.3	1.3	1.2	1.3	1.2	0.7	1.1	0.3	0.7	0.5	0.4	0.5	0.7	1.2	1.0	0.7	−0.0	0.7	0.6
Free cash flow $B	1.2	1.4	1.5	1.0	1.3	0.8	0.9	0.9	0.7	0.7	0.4	0.5	1.0	1.0	1.1	0.6	0.3	0.6	0.8
EPS, diluted $	4.57	4.43	4.19	4.18	3.94	2.30	3.37	0.97	2.10	1.40	1.20	1.62	2.13	3.27	2.85	1.94	−0.09	1.87	1.57
Dividend / sh $	0.99	0.94	0.90	0.84	0.78	0.72	0.66	0.60	0.53	0.46	0.40	0.53	0.46	0.30	0.00	0.00	·	·	·
Payout %	22	21	21	20	20	31	19	60	25	32	33	32	21	9	0	0	·	·	·
ROE %	20.6	22.0	22.2	23.5	23.6	14.9	23.0	6.7	15.1	11.0	8.5	10.4	14.0	24.3	26.9	23.9	−1.2	23.9	19.7
Shares out B	0.28	0.29	0.29	0.30	0.30	0.31	0.31	·	·	·	·	·	·	·	·	·	·	·	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 74 reconciliationsAUDITED

Reconciled in 19 of 19 fiscal years. 2 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityLaboratory Analytical Instruments

Listed onNYSE

Incorporated inDelaware

Fiscal year endsOctober 31

Data on record since2007